BHVN · Company research
Biohaven Ltd. (BHVN): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Biohaven (BHVN) Short Interest & Short Float | Updated Oct 2026 - MarketBeat | Biohaven (BHVN) Short Interest & Short Float | Updated Oct 2026 MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| Biohaven Ltd. (BHVN) Stock Price, News, Quote & History - Yahoo! Finance Canada | Biohaven Ltd. (BHVN) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance Singapore | Biohaven Ltd. (BHVN) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 8, 2026 | neutral | 0 | 0.6 |
| Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement - Benzinga | Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement Benzinga | View source ↗ | Benzinga | Oct 8, 2026 | neutral | 0 | 0.6 |
| A Phase 3 Graves’ disease drug is part of a deal that could pay Biohaven up to $100 million. - Stock Titan | A Phase 3 Graves’ disease drug is part of a deal that could pay Biohaven up to $100 million. Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development | Bexorg, a precision neurology company, received up to $28.3 million in funding from ARPA-H to extend its BrainEx perfusion technology from 24 hours to two weeks. This advancement will enable longitudinal studies of human brain pharmacology and drug responses, potentially reducing CNS drug development attrition by providing richer human brain data for AI model training and clinical trial design. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 1 | 1 |
| Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development | Bexorg, a precision neurology company, received up to $28.3 million in funding from ARPA-H to extend its BrainEx perfusion technology from 24 hours to two weeks. This advancement will enable longitudinal studies of human brain pharmacology and drug responses, potentially reducing CNS drug development attrition by providing richer human brain data for AI model training and clinical trial design. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 1 | 1 |
| BHVN News | BIOHAVEN LTD (NYSE:BHVN) - ChartMill | BHVN News | BIOHAVEN LTD (NYSE:BHVN) ChartMill | View source ↗ | ChartMill | Oct 6, 2026 | neutral | 0 | 0.6 |
| BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts - Stocktwits | BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts Stocktwits | View source ↗ | Stocktwits | Oct 4, 2026 | neutral | 0 | 0.6 |
| Biohaven's cancer drug produced tumor shrinkage in heavily pretreated patients - Stock Titan | Biohaven's cancer drug produced tumor shrinkage in heavily pretreated patients Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| Why Biohaven Stock Was Rocking the Market This Week - Yahoo Finance | Why Biohaven Stock Was Rocking the Market This Week Yahoo Finance | View source ↗ | Yahoo Finance | Aug 28, 2026 | neutral | 0 | 0.6 |
| Why Biohaven Ltd. (BHVN) Stock Is Up Today - Quiver Quantitative | Why Biohaven Ltd. (BHVN) Stock Is Up Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 26, 2026 | neutral | 0 | 0.6 |
| Biohaven BHVN Stock Pops As Analysts Hike Targets - StocksToTrade | Biohaven BHVN Stock Pops As Analysts Hike Targets StocksToTrade | View source ↗ | StocksToTrade | Aug 26, 2026 | neutral | 0 | 0.6 |
| BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout - Stocktwits | BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout Stocktwits | View source ↗ | Stocktwits | Aug 26, 2026 | neutral | 0 | 0.6 |
| BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout - Yahoo Finance | BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout Yahoo Finance | View source ↗ | Yahoo Finance | Aug 26, 2026 | neutral | 0 | 0.6 |
| Why Is BHVN Stock Falling Premarket? - Stocktwits | Why Is BHVN Stock Falling Premarket? Stocktwits | View source ↗ | Stocktwits | Jun 30, 2026 | neutral | 0 | 0.6 |
| What's Going On With Biohaven Stock Monday? - Biohaven (NYSE:BHVN) - Benzinga | What's Going On With Biohaven Stock Monday? - Biohaven (NYSE:BHVN) Benzinga | View source ↗ | Benzinga | Jun 29, 2026 | neutral | 0 | 0.6 |
| Is Biohaven (BHVN) the Best Stock That Have the Potential to Rise 1000%? - Yahoo Finance | Is Biohaven (BHVN) the Best Stock That Have the Potential to Rise 1000%? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 5, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.